Currently out of the existing stock ratings of Sara Nik, 9 are a BUY (100%).

Sara Nik

Work Performance Price Targets & Ratings Chart

Analyst Sara Nik, carries an average stock price target met ratio of 50% that have a potential upside of 30.49% achieved within 40 days.

Sara Nik’s has documented 17 price targets and ratings displayed on 3 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on CRIS, Curis at 17-Aug-2026.

Wall Street Analyst Sara Nik

Analyst best performing recommendations are on CDTX (CIDARA THERAPEUTICS).
The best stock recommendation documented was for CDTX (CIDARA THERAPEUTICS) at 10/21/2025. The price target of $150 was fulfilled within 24 days with a profit of $46.78 (45.32%) receiving and performance score of 18.88.

Average potential price target upside

MBRX Moleculin Biotech CRIS Curis CDTX Cidara Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 10-Sep-2025

$22

$18.73 (572.78%)

$4

6 months 8 days ago
(24-Mar-2026)

1/2 (50%)

$19.75 (877.78%)

99

Buy Since 09-Jun-2025

$4

$0.73 (22.32%)

$4

1 years 3 months 14 days ago
(18-Jun-2025)

2/2 (100%)

$-10.58 (-72.57%)

188

Buy Since 14-Dec-2023

$8

1 years 6 months 7 days ago
(25-Mar-2025)

3/3 (100%)

$-18.5 (-69.81%)

190

Hold Since 25-Mar-2025

$4

$0.73 (22.32%)

1 years 6 months 7 days ago
(25-Mar-2025)

1/1 (100%)

$-24.75 (-86.09%)

268

Buy Since 14-Apr-2021

$30

$26.73 (817.43%)

2 years 1 months 18 days ago
(14-Aug-2024)

3/3 (100%)

$-32.5 (-52.00%)

380

Show more analysts

Please expand the browser size to see the chart

Which stock is Sara Nik most bullish on?

Potential upside of $42 has been obtained for CRIS (CURIS)
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?